Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Senotherapy
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Emerging Longevity Ventures
Deal Size : $4.7 million
Deal Type : Financing
Senisca Secures Additional £3.7 Million Financing for Senotherapeutic Platform Development
Details : The proceeds will support the development of senotherapeutic programs targeting age-related disease through RNA splicing regulation, resulting in cellular reprogramming by attenuating senescence.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Undisclosed
March 18, 2024
Lead Product(s) : Senotherapy
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Emerging Longevity Ventures
Deal Size : $4.7 million
Deal Type : Financing